(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of 19.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Arrowhead Pharmaceuticals's revenue in 2026 is $669,495,000.On average, 19 Wall Street analysts forecast ARWR's revenue for 2027 to be $42,764,789,884, with the lowest ARWR revenue forecast at $15,809,199,947, and the highest ARWR revenue forecast at $78,756,428,076. On average, 13 Wall Street analysts forecast ARWR's revenue for 2028 to be $99,217,137,621, with the lowest ARWR revenue forecast at $44,297,400,851, and the highest ARWR revenue forecast at $215,695,571,109.
In 2029, ARWR is forecast to generate $165,267,726,390 in revenue, with the lowest revenue forecast at $126,787,184,490 and the highest revenue forecast at $226,713,419,535.